Pharmaceutical Market Europe • October 2020 • 5
CONTENTS
NEWS & COLUMNS
6-7 NEWS
2020 ESMO virtual congress round-up; Gilead agrees $21bn buy-out of Immunomedics
8-11 CORONAVIRUS NEWS
AZ's COVID-19 vaccine trial resumes in the UK; Eli Lilly's COVID-19 targeting antibody shows promise
12 DARWIN'S MEDICINE
Bayer's drop of the future
13 POLICY AND PUBLIC HEALTH
Warren Buffett's greatest health lesson
14 GETTING THE BALANCE RIGHT
The new normal for UK healthcare comms
15 PRAISING THE MEDICAL TEAM
Why great medics are important in a launch team
FEATURES
16-17 COVID-19: A CATALYST FOR TECHNOLOGY ADOPTION IN CLINICAL TRIALS
The COVID-19 crisis may prove to be a catalyst that transforms the approach to trials for good
20-22 VACCINES FOR COVID-19 AND OTHER DISEASES
As the world waits anxiously for a SARS-CoV-2 vaccine, will COVID-19 help or hinder the quest to increase uptake of other vaccinations?
24-25 GSK'S RESEARCH INTO THE POTENTIAL OF EOSINOPHILS
A rich diversity of pharma and biotech companies sustain activity and help
maintain its reputation as a highly innovative country
COMMUNIQUE
MARKETING & COMMS
28-30 THE CHALLENGE OF CROWDED DIGITAL CHANNELS
Chris Ross explores the pursuit of communications excellence in a world of noise
34-35 THE SCIENCE OF THE DEAL
Business development is more like child-raising than you might think
36-37 OUR BEST BEHAVIOUR
Why driving behaviour change is the next big focus
38-40 NICE – BUT NOT ENOUGH
Why a NICE recommendation isn't a guarantee of product uptake
41 ASSOCIATION CONGRESSES
Reimagining the rules of engagement
45 HEALTHCARE COMMS
Publicis Health launches a new agency; Porterhouse Medical Group opens a new hub
46 PEOPLE
Q&A with Caroline Gosling
CAREERS & RECRUITMENT
42-44 APPOINTMENTS
Changes at Moderna, Sanofi Espoir and Ipsen
47 PHARMA MARKETING JOBS
Jobs in pharma marketing, sales and communications